Tvardi Therapeutics, Inc. (NASDAQ: TVRD) announced on November 19, 2026, that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding its pre-Investigational New Drug (pre-IND) meeting request for TTI-109. The company is developing TTI-109, a next-generation oral STAT3 inhibitor, with the goal of treating inflammatory bowel disease (IBD).

The FDA provided constructive feedback on the company's plans for Phase 2 development of TTI-109 in ulcerative colitis (UC), which is the company's initial indication. Additionally, the agency offered guidance on the types of nonclinical studies, dosing, study design, and patient selection required to support an IND submission. The feedback also supports advancing both UC and Crohn's disease (CD), the other major form of IBD, either in parallel or sequentially.

Tvardi plans to incorporate the FDA's guidance and submit an IND in 2027. The initiation of the Phase 2 study remains subject to FDA review and clearance of the IND submission, as well as the availability of additional funding.

In conjunction with the regulatory update, Tvardi reported new data from its Phase 1 study. An analysis of exposure data suggests that TTI-109 has the potential to provide sustained inhibition of STAT3 at proposed clinical doses, with minimal predicted effect on STAT1 and STAT5. The company notes that this selectivity profile differs from that of Janus kinase (JAK) inhibitors, which inhibit multiple STAT pathways and carry boxed warnings for serious adverse events.

TTI-109 is an orally administered prodrug of TTI-101. In the Phase 1 healthy volunteer study, TTI-109 demonstrated reductions in cellular and humoral immune populations known to correlate with UC disease severity, providing pharmacodynamic evidence of target engagement.